Palisade Bio IncNASDAQ:PALINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.6800
- TODAY'S CHANGE (%)-0.3900 (-7.6923%)
- Bid / Lots4.6700/ 1
- Ask / Lots4.7100/ 4
- Open / Previous Close4.6800 / 5.0700
- Day Range
- 52 Week Range
- Volume97,244
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PALI |
|---|---|---|
| 09:32 ET | 9042 | 4.53 |
| 09:34 ET | 10879 | 4.578 |
| 09:36 ET | 195 | 4.6 |
| 09:38 ET | 1000 | 4.79 |
| 09:39 ET | 3050 | 4.7482 |
| 09:41 ET | 1000 | 4.8486 |
| 09:45 ET | 300 | 4.6706 |
| 09:48 ET | 900 | 4.745 |
| 09:50 ET | 400 | 4.65 |
| 09:52 ET | 8208 | 4.69 |
| 09:54 ET | 1302 | 4.92 |
| 10:01 ET | 100 | 4.9 |
| 10:03 ET | 400 | 4.91 |
| 10:10 ET | 100 | 4.88 |
| 10:12 ET | 7952 | 4.8 |
| 10:14 ET | 1875 | 4.9001 |
| 10:15 ET | 860 | 4.79 |
| 10:17 ET | 3218 | 4.7 |
| 10:24 ET | 100 | 4.76 |
| 10:26 ET | 350 | 4.74 |
| 10:28 ET | 200 | 4.7 |
| 10:30 ET | 1112 | 4.77 |
| 10:32 ET | 400 | 4.7744 |
| 10:33 ET | 100 | 4.67 |
| 10:37 ET | 200 | 4.67 |
| 10:42 ET | 1300 | 4.74 |
| 10:48 ET | 100 | 4.6986 |
| 10:50 ET | 411 | 4.69 |
| 11:02 ET | 500 | 4.62 |
| 11:04 ET | 3950 | 4.51 |
| 11:06 ET | 576 | 4.62 |
| 11:08 ET | 366 | 4.5 |
| 11:13 ET | 400 | 4.57 |
| 11:15 ET | 3300 | 4.6106 |
| 11:18 ET | 100 | 4.5935 |
| 11:22 ET | 130 | 4.55 |
| 11:24 ET | 100 | 4.555 |
| 11:26 ET | 619 | 4.555 |
| 11:31 ET | 300 | 4.555 |
| 11:33 ET | 2405 | 4.58 |
| 11:36 ET | 100 | 4.58 |
| 11:40 ET | 100 | 4.51 |
| 11:42 ET | 100 | 4.53 |
| 11:44 ET | 100 | 4.54 |
| 11:45 ET | 4400 | 4.58 |
| 11:49 ET | 1000 | 4.65 |
| 11:54 ET | 100 | 4.61 |
| 12:02 ET | 100 | 4.62 |
| 12:03 ET | 506 | 4.61 |
| 12:05 ET | 2100 | 4.59 |
| 12:14 ET | 100 | 4.58 |
| 12:18 ET | 2370 | 4.59 |
| 12:30 ET | 620 | 4.66 |
| 12:50 ET | 300 | 4.69 |
| 12:56 ET | 100 | 4.67 |
| 12:59 ET | 211 | 4.68 |
| 01:08 ET | 200 | 4.68 |
Apr 16, 2024
DJ Palisade Bio Is Maintained at Buy by Maxim Group, from 1:37PM ET on Tuesday Apr 16, 2024 by Dow Jones
1:37PM ET on Tuesday Apr 16, 2024 by Dow JonesDJ Palisade Bio Shares Surge 80% After Lab Study Results for Ulcerative Colitis Treatment, from 10:14AM ET on Tuesday Apr 16, 2024 by Dow Jones
10:14AM ET on Tuesday Apr 16, 2024 by Dow JonesPalisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 16, 2024 by Dow JonesPalisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 11, 2024
Palisade Bio to Participate in the Virtual Investor Lunch Break Event, from 9:15AM ET on Thursday Apr 11, 2024 by Dow Jones
9:15AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Palisade Bio Inc | 4.3M | -0.2x | --- |
Marizyme Inc | 4.4M | -0.1x | --- |
Halberd Corp | 5.1M | 3.3x | --- |
Yield10 Bioscience Inc | 4.2M | -0.1x | --- |
Finch Therapeutics Group Inc | 3.8M | 0.0x | --- |
Axim Biotechnologies Inc | 4.3M | -0.4x | --- |
Company Information
Palisade Bio, Inc. is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company’s approach is founded on the discovery that damage to the intestinal epithelial barrier can result in the leakage of digestive enzymes from the gastrointestinal (GI) tract into the peritoneal cavity, which can damage tissues and promote inflammation, causing a broad array of acute and chronic conditions. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the well-characterized digestive enzyme inhibitor tranexamic acid (TXA), which is being developed for administration prior to surgeries that are at risk of disrupting the intestinal epithelial barrier. LB1148 is formulated as an aqueous solution for oral (enteral) administration. In addition to TXA, the LB1148 formulation contains polyethylene glycol, carbohydrates, and electrolytes.
Contact Information
- Headquarters
- 7750 El Camino Real, Suite 5200CARLSBAD, CA, United States 92009
- Phone
- 858-704-4900
- Fax
- 302-697-4597
Executives
- Independent Chairman of the Board
- Donald Williams
- Interim Chief Executive Officer, Chief Financial Officer, Director
- J. D. Finley
- Chief Operating Officer
- Robert Mcrae
- Chief Medical Officer
- Mitchell Jones
- Independent Director
- Binxian Wei
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3M |
|---|---|
Revenue (TTM) | $250.0K |
Shares Outstanding | 851.4K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.30 |
EPS | $-28.22 |
Book Value | $18.30 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 17.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,228.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
